170 related articles for article (PubMed ID: 36261705)
1. Learning to distinguish progressive and non-progressive ductal carcinoma in situ.
Casasent AK; Almekinders MM; Mulder C; Bhattacharjee P; Collyar D; Thompson AM; Jonkers J; Lips EH; van Rheenen J; Hwang ES; Nik-Zainal S; Navin NE; Wesseling J;
Nat Rev Cancer; 2022 Dec; 22(12):663-678. PubMed ID: 36261705
[TBL] [Abstract][Full Text] [Related]
2. Ductal Carcinoma In Situ - Quo Vadis?
Peltecu G
Chirurgia (Bucur); 2021 Dec; 116(5 Suppl):S5-S6. PubMed ID: 34967322
[TBL] [Abstract][Full Text] [Related]
3. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
4. Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ?
Graña-López L; Herranz M; Domínguez-Prado I; Argibay S; Villares Á; Vázquez-Caruncho M
Eur Radiol; 2020 Jan; 30(1):514-522. PubMed ID: 31375867
[TBL] [Abstract][Full Text] [Related]
5. Ductal Carcinoma in Situ: Molecular Changes Accompanying Disease Progression.
Wilson GM; Dinh P; Pathmanathan N; Graham JD
J Mammary Gland Biol Neoplasia; 2022 Mar; 27(1):101-131. PubMed ID: 35567670
[TBL] [Abstract][Full Text] [Related]
6. Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma
Pareja F; Brown DN; Lee JY; Da Cruz Paula A; Selenica P; Bi R; Geyer FC; Gazzo A; da Silva EM; Vahdatinia M; Stylianou AA; Ferrando L; Wen HY; Hicks JB; Weigelt B; Reis-Filho JS
Clin Cancer Res; 2020 Jul; 26(14):3682-3693. PubMed ID: 32220886
[TBL] [Abstract][Full Text] [Related]
7. Everybody needs good neighbours: the progressive DCIS microenvironment.
Gibson SV; Roozitalab RM; Allen MD; Jones JL; Carter EP; Grose RP
Trends Cancer; 2023 Apr; 9(4):326-338. PubMed ID: 36739265
[TBL] [Abstract][Full Text] [Related]
8. Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).
Groen EJ; Elshof LE; Visser LL; Rutgers EJT; Winter-Warnars HAO; Lips EH; Wesseling J
Breast; 2017 Feb; 31():274-283. PubMed ID: 27671693
[TBL] [Abstract][Full Text] [Related]
9. Progression from ductal carcinoma in situ to invasive breast cancer: revisited.
Cowell CF; Weigelt B; Sakr RA; Ng CK; Hicks J; King TA; Reis-Filho JS
Mol Oncol; 2013 Oct; 7(5):859-69. PubMed ID: 23890733
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening.
Trentham-Dietz A; Ergun MA; Alagoz O; Stout NK; Gangnon RE; Hampton JM; Dittus K; James TA; Vacek PM; Herschorn SD; Burnside ES; Tosteson ANA; Weaver DL; Sprague BL
Breast Cancer Res Treat; 2018 Feb; 168(1):229-239. PubMed ID: 29185118
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral Heterogeneity in Ductal Carcinoma In Situ: Chaos and Consequence.
Sinha VC; Piwnica-Worms H
J Mammary Gland Biol Neoplasia; 2018 Dec; 23(4):191-205. PubMed ID: 30194658
[TBL] [Abstract][Full Text] [Related]
12. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
[TBL] [Abstract][Full Text] [Related]
13. miRNAs as Biomarkers for Predicting the Progression of Ductal Carcinoma in Situ.
Hannafon BN; Ding WQ
Am J Pathol; 2018 Mar; 188(3):542-549. PubMed ID: 29246496
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study.
Williams LA; Casbas-Hernandez P; Nichols HB; Tse CK; Allott EH; Carey LA; Olshan AF; Troester MA
PLoS One; 2019; 14(1):e0211488. PubMed ID: 30682163
[TBL] [Abstract][Full Text] [Related]
15. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.
Mardekian SK; Bombonati A; Palazzo JP
Hum Pathol; 2016 Mar; 49():114-23. PubMed ID: 26826418
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma
Visser LL; Elshof LE; Schaapveld M; van de Vijver K; Groen EJ; Almekinders MM; Bierman C; van Leeuwen FE; Rutgers EJ; Schmidt MK; Lips EH; Wesseling J
Clin Cancer Res; 2018 Aug; 24(15):3593-3601. PubMed ID: 29685879
[No Abstract] [Full Text] [Related]
17. The molecular journey from ductal carcinoma in situ to invasive breast cancer.
Wiechmann L; Kuerer HM
Cancer; 2008 May; 112(10):2130-42. PubMed ID: 18383519
[TBL] [Abstract][Full Text] [Related]
18. Ductal Carcinoma In Situ of Breast: From Molecular Etiology to Therapeutic Management.
Hophan SL; Odnokoz O; Liu H; Luo Y; Khan S; Gradishar W; Zhou Z; Badve S; Torres MA; Wan Y
Endocrinology; 2022 Apr; 163(4):. PubMed ID: 35245349
[TBL] [Abstract][Full Text] [Related]
19. A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.
Van Bockstal MR; Agahozo MC; Koppert LB; van Deurzen CHM
Int J Cancer; 2020 Mar; 146(5):1189-1197. PubMed ID: 31018242
[TBL] [Abstract][Full Text] [Related]
20. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.
Sharma M; Beck AH; Webster JA; Espinosa I; Montgomery K; Varma S; van de Rijn M; Jensen KC; West RB
Breast Cancer Res Treat; 2010 Sep; 123(2):397-404. PubMed ID: 19949854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]